Brigitte Sigal‐Zafrani

7.2k citations

110 papers · 4.5k indexed · 1 hit paper · h-index 36

Cancer Research top 0.5%
- Breast Cancer Treatment Studies 58
- Cancer Genomics and Diagnostics 21
Oncology top 1%
- HER2/EGFR in Cancer Research 24
- Cancer Cells and Metastasis 12
- Cancer Treatment and Pharmacology 11
Pathology and Forensic Medicine top 1%
- Breast Lesions and Carcinomas 31
Dermatology top 2%
- Cancer and Skin Lesions 9
Radiology, Nuclear Medicine and Imaging top 2%
Genetics
- BRCA gene mutations in cancer 14

Co-authors: Anne Vincent‐Salomon Xavier Sastre‐Garau Alain Fourquet Rémy Salmon Marc A. Bollet Dominique Stoppa‐Lyonnet Jean‐Yves Pierga Youlia Kirova
Cited by: Cancer Research Oncology Pathology and Forensic Medicine
Journals: Journal of Clinical Oncology (7 papers)PLoS ONE (10 papers)The Journal of Clinical Endocrinology & Metabolism (1 paper)
Partner nations: France United States Mali

In The Last Decade

Brigitte Sigal‐Zafrani

107 papers receiving 4.4k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Brigitte Sigal‐Zafrani

Since Specialization

Citations

This map shows the geographic impact of Brigitte Sigal‐Zafrani's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brigitte Sigal‐Zafrani with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brigitte Sigal‐Zafrani more than expected).

Fields of papers citing papers by Brigitte Sigal‐Zafrani

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brigitte Sigal‐Zafrani. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brigitte Sigal‐Zafrani. The network helps show where Brigitte Sigal‐Zafrani may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Brigitte Sigal‐Zafrani, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Brigitte Sigal‐Zafrani Line = papers co-authored together Brigitte Sigal‐Zafrani links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Medico-economic impact of MSKCC non-sentinel node prediction nomogram for ER-positive HER2-negative breast cancers PLoS ONE ·Hélène Bonsang‐Kitzis,Delphine Mouttet-Boizat,Eugénie Guillot,Jean-Guillaume Féron,Virginie Fourchotte,S. Alran,Jean‐Yves Pierga,Paul Cottu,Florence Lerebours,Denise Stevens,Anne Vincent‐Salomon,Brigitte Sigal‐Zafrani,François Campana,Roman Rouzier,Fabien Reyal	2017	4
2	Characterization of Breast Cancer Preclinical Models Reveals a Specific Pattern of Macrophage Polarization PLoS ONE ·David Vallerand,Gérald Massonnet,F. Z. El Kébir,David Gentien,Zofia Maciorowski,Pierre de la Grange,Brigitte Sigal‐Zafrani,Marion Richardson,Sandrine Humbert,Aurélie Thuleau,Franck Assayag,Ludmilla de Plater,Nicolás André,Suzy Scholl,Elisabetta Marangoni,Stefan Weigand,Sergio Roman‐Roman,Ariel Savina,Didier Decaudin	2016	9
3	Breast Cancer Cell–Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes Cancer Research ·Cristina Ghirelli,Fabien Reyal,Marine Jeanmougin,Raphaël Zollinger,Philémon Sirven,Paula Michea,Christophe Caux,Nathalie Bendriss‐Vermare,Marie‐Hélène Donnadieu,Martial Caly,Virginie Fourchotte,Anne Vincent‐Salomon,Brigitte Sigal‐Zafrani,Xavier Sastre‐Garau,Vassili Soumelis	2015	46
4	Genomic hallmarks of homologous recombination deficiency in invasive breast carcinomas International Journal of Cancer ·Élodie Manié,Tatiana Popova,Aude Battistella,Julien Tarabeux,Virginie Caux‐Moncoutier,Lisa Golmard,Nicholas K. Smith,Christopher R. Mueller,Odette Mariani,Brigitte Sigal‐Zafrani,Thierry Dubois,Anne Vincent‐Salomon,Claude Houdayer,Dominique Stoppa‐Lyonnet,Marc‐Henri Stern	2015	51
5	Challenging single- and multi-probesets gene expression signatures of pathological complete response to neoadjuvant chemotherapy in breast cancer: Experience of the REMAGUS 02 phase II trial The Breast ·Fabien Valet,Patricia de Crémoux,F. Spyratos,Nicolas Servant,M.E. Dujaric,David Gentien,Jacqueline Lehmann‐Che,Véronique Scott,Brigitte Sigal‐Zafrani,M-C Mathieu,P Bertheau,Guinebretière Jm,Jean‐Yves Pierga,Suzette Delaloge,Sylvie Giacchetti,Étienne Brain,O. Tembo,M. Marty,Bernard Asselain	2013	11
6	Ploidy and Large-Scale Genomic Instability Consistently Identify Basal-like Breast Carcinomas with BRCA1/2 Inactivation Cancer Research ·Tatiana Popova,Élodie Manié,Guillaume Rieunier,Virginie Caux‐Moncoutier,Carole Tirapo,Thierry Dubois,Olivier Delattre,Brigitte Sigal‐Zafrani,Marc A. Bollet,Michel Longy,Claude Houdayer,Xavier Sastre‐Garau,Anne Vincent‐Salomon,Dominique Stoppa‐Lyonnet,Marc‐Henri Stern	2012	418
7	Search for a Gene Expression Signature of Breast Cancer Local Recurrence in Young Women Clinical Cancer Research ·Nicolas Servant,Marc A. Bollet,Hans Halfwerk,Kevin Bleakley,Bas Kreike,Laurent Jacob,Daoud Sie,Ron Kerkhoven,Philippe Hupé,Rim Hadhri,Alain Fourquet,Harry Bartelink,Emmanuel Barillot,Brigitte Sigal‐Zafrani,Marc J. van de Vijver	2012	55
8	Non-Sentinel Lymph Node Metastasis Prediction in Breast Cancer with Metastatic Sentinel Lymph Node: Impact of Molecular Subtypes Classification PLoS ONE ·Fabien Reyal,C. Bélichard,Roman Rouzier,E. De Gournay,Claire Sénéchal,François‐Clément Bidard,Jean‐Yves Pierga,Paul Cottu,Florence Lerebours,Youlia Kirova,Jean-Guillaume Féron,Virginie Fourchotte,Anne Vincent‐Salomon,Jean‐Marc Guinebretière,Brigitte Sigal‐Zafrani,Xavier Sastre‐Garau,Yann De Rycke,Charles Coutant	2012	17
9	Breast and ovarian cancer risk management in a French cohort of 158 women carrying a BRCA1 or BRCA2 germline mutation: patient choices and outcome Familial Cancer ·Pascale This,Anne de la Rochefordière,Alexia Savignoni,Marie Christine Falcou,A. Tardivon,Fabienne Thibault,S. Alran,V. Fourchotte,Alfred Fitoussi,Benoît Couturaud,Sylvie Dolbeault,Rémy Salmon,Brigitte Sigal‐Zafrani,Bernard Asselain,Dominique Stoppa‐Lyonnet	2012	13
10	High Ki67 expression is a risk marker of invasive relapse for classical lobular carcinoma in situ patients The Breast ·Anne Vincent‐Salomon,David Hajage,Alexandre Rouquette,Aurélie Cédenot,Nadège Gruel,S. Alran,Xavier Sastre‐Garau,Brigitte Sigal‐Zafrani,Alain Fourquet,Youlia Kirova	2012	10
11	A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients Breast Cancer Research and Treatment ·Jean‐Yves Pierga,Suzette Delaloge,Marc Espié,Étienne Brain,Brigitte Sigal‐Zafrani,Marie‐Christine Mathieu,Philippe Bertheau,Jean Marc Guinebretière,M. Spielmann,Alexia Savignoni,M. Marty	2010	85
12	Lobular phenotype related to occult-metastatic spread in axillary sentinel node and/or bone marrow in breast carcinoma European Journal of Cancer ·Anne Vincent‐Salomon,Martial Caly,Yann De Rycke,Paul Fréneaux,Jerzy Klijanienko,Marick Laé,Frédérique Viard,Claude Nos,François‐Clément Bidard,S. Alran,Rémy Salmon,Youlia Kirova,Jean‐Yves Pierga,Brigitte Sigal‐Zafrani,Xavier Sastre‐Garau	2009	7
13	Integrated Genomic and Transcriptomic Analysis of Ductal Carcinoma In situ of the Breast Clinical Cancer Research ·Anne Vincent‐Salomon,Carlo Lucchesi,Nadège Gruel,Virginie Raynal,Gaëlle Pierron,Rémi Goudefroye,Fabien Reyal,François Radvanyi,Rémy Salmon,Jean Paul Thiery,Xavier Sastre‐Garau,Brigitte Sigal‐Zafrani,Alain Fourquet,Olivier Delattre,(unknown)	2008	114
14	HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management? British Journal of Cancer ·Anne Vincent‐Salomon,J-Y Pierga,J Couturier,Catherine Dubois d’Enghien,Claude Nos,Brigitte Sigal‐Zafrani,Marick Laé,Paul Fréneaux,Véronique Dièras,Jean Paul Thiery,Xavier Sastre‐Garau	2007	46
15	Identification of typical medullary breast carcinoma as a genomic sub-group of basal-like carcinomas, a heterogeneous new molecular entity Breast Cancer Research ·Anne Vincent‐Salomon,Nadège Gruel,Carlo Lucchesi,Gaëtan MacGrogan,R. Dendale,Brigitte Sigal‐Zafrani,Michel Longy,Virginie Raynal,Gaëlle Pierron,Isabelle de Mascarel,Taris Corinne,Dominique Stoppa‐Lyonnet,Jean‐Yves Pierga,Rémy Salmon,Xavier Sastre‐Garau,Alain Fourquet,Olivier Delattre,Patricia de Crémoux,Alain Aurias	2007	133
16	Neoadjuvant chemotherapy for invasive lobular carcinomas of the breast: a poorer response rate but not a worse prognosis than invasive ductal carcinoma Breast Cancer Research and Treatment ·Anne Vincent‐Salomon,J-Y Pierga,Chantal Gautier,Brigitte Sigal‐Zafrani,Paul Fréneaux,M. Laé,Christophe Rosty,B Asselain,R.J. Salmon,Xavier Sastre‐Garau	2005	9
17	Stereotactic Radioguided Surgery by SiteSelect for Subclinical Mammographic Lesions Annals of Surgical Oncology ·Virginie Doridot,Martine Meunier,Carl El Khoury,Claude Nos,Anne Vincent‐Salomon,Brigitte Sigal‐Zafrani,Krishna B. Clough	2005	9
18	Increased cell size and Akt activation in HER‐2/neu‐overexpressing invasive ductal carcinoma of the breast Histopathology ·Xavier Sastre‐Garau,Pierre Génin,Antoine Rousseau,Abir Al Ghuzlan,Nicolás André,Paul Fréneaux,Christophe Rosty,Brigitte Sigal‐Zafrani,J Couturier,Jean Paul Thiery,H Magdelénat,Anne Vincent‐Salomon	2004	14
19	Breast-conserving therapy for breast cancer Cancer/Radiothérapie ·Claude Nos,Virginie Doridot,Alain Fourquet,K.B. Clough,Brigitte Sigal‐Zafrani,J.S. Aucouturier	2004	2
20	[Tamoxifen and aromatase inhibitors in the treatment of breast cancer in menopausal women: pharmacological and clinical aspects]. PubMed ·Patricia de Crémoux,Véronique Dièras,Marie‐France Poupon,H Magdelénat,Brigitte Sigal‐Zafrani,Alain Fourquet,Jean‐Yves Pierga	2004	8

About Brigitte Sigal‐Zafrani

Brigitte Sigal‐Zafrani is a scholar working on Cancer Research, Oncology and Pathology and Forensic Medicine, having authored 110 papers that have together received 4.5k indexed citations. Recurring topics across this work include Breast Cancer Treatment Studies (58 papers), Breast Lesions and Carcinomas (31 papers), HER2/EGFR in Cancer Research (24 papers), Cancer Genomics and Diagnostics (21 papers), BRCA gene mutations in cancer (14 papers), Cancer Cells and Metastasis (12 papers), Cancer Treatment and Pharmacology (11 papers) and Cancer and Skin Lesions (9 papers). The work is most often cited by research in Cancer Research (2.2k citations), Oncology (2.3k citations) and Pathology and Forensic Medicine (1.1k citations). Brigitte Sigal‐Zafrani has collaborated with scholars based in France, United States and Mali. Frequent co-authors include Anne Vincent‐Salomon, Xavier Sastre‐Garau, Alain Fourquet, Rémy Salmon, Marc A. Bollet, Dominique Stoppa‐Lyonnet, Jean‐Yves Pierga, Youlia Kirova, Olivier Delattre and Alexia Savignoni. Their work appears in journals such as Journal of Clinical Oncology, PLoS ONE and The Journal of Clinical Endocrinology & Metabolism.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact